Similar studies in other cancers (breast, lung, bladder, prostate, ...) confirmed that overexpression of N-CAD protein was associated with poor treatment outcomes, cell migration, angiogenesis, disease aggressiveness, and metastasis (25–29). Here, CDH2 is linked to cancer.